Overexpression of Semaphorin-3A and Semaphorin-4D in the Peripheral Blood from Newly Diagnosed Patients with Chronic Lymphocytic Leukemia

• Published in: International journal of hematology- oncology and stem cell research Vol. 13; no. 1; pp. 25 - 34
• Main Authors: Parsa, Somayeh, Sharifzadeh, Sedigheh, Monabati, Ahmad, Seyyedi, Noorossadat, Ranjbaran, Reza, Baghbani, Mohammad Reza, Nemati, Maryam, Jafarzadeh, Abdollah
• Format: Journal Article
• Language: English
• Published: Iran Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 01.01.2019; Tehran University of Medical Sciences
• Subjects: Chronic lymphocytic leukemia; Semaphorins; SEMA3A; SEMA4A; SEMA4D; Original; SEMA4A; Chronic lymphocytic leukemia; SEMA4D; Semaphorins; SEMA3A
• ISSN: 2008-2207; 2008-3009; 2008-2207
• DOI: 10.18502/ijhoscr.v13i1.322

Background: Semaphorins play prominent roles in physiological and pathological processes such as vascular development, tumor growth and immune responses. Semaphorins have different roles in various kinds of cancers, but there is no study concerning their expression in the chronic lymphocytic leukemia (CLL). This study aimed to assess the SEMA3A, SEMA4A and SEMA4D expression in patients with CLL.  Materials and Methods: Peripheral blood specimens were collected from 30 newly-diagnosed untreated patients with CLL and 30 healthy subjects as a control group. The SEMA3A, SEMA4A and SEMA4D expression was determined by real-time PCR method.  Results: The fold change expression of SEMA3A and SEMA4D was 7.58 ± 2.66 and 3.20 ± 0.99 in patients with CLL, and was 1.01 ± 0.31 and 1.00 ± 0.27 in healthy subjects, respectively. The CLL patients expressed higher amounts of SEMA3A and SEMA4D in comparison with healthy subjects (P<0.02 and P<0.03, respectively). The fold change expression of SEMA3A in patients with stage II (11.12 ± 5.35) was also higher than patients with stage I (4.49 ± 1.61, P<0.05). No significant difference was also observed in the expression of SEMA4A and SEMA4D between patients with stage I and stage II CLL. In both CLL and control groups, the fold change expression of SEMA3A was higher in men than in women (P<0.03 and P<0.02, respectively). Conclusion: The results of the study indicated elevated expression of the SEMA3A and SEMA4D in patients with CLL. The SEMA3A expression was influenced by tumor stage and gender of participants.